101223 Nasal Polyps CME
Surgery or Biologic for Nasal Polyps? A Close Look at the Evidence
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Asthma and Allergy Foundation of America (AAFA)
ACKNOWLEDGEMENT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
DATE OF RELEASE/EXPIRATION
October 12th, 2023 from 2:00pm-3:00pmET
TARGET AUDIENCE
The intended audience for this program is ENTs, allergists, immunologists, specialty nurse practitioners and PAs, and other clinicians involved in the management of patients with nasal polyps.
STATEMENT OF NEED/PROGRAM OVERVIEW
As management strategies for nasal polyps (NPs) have evolved, patients whose NPs do not respond to initial treatment, who are ineligible for systemic corticosteroids, or whose NPs recur after initial surgery often undergo repeated surgeries, with high associated costs and complication risks. Clinicians—including ear, nose, and throat specialists (ENTs) and allergists—need to be aware of the latest strategies to personalize NP care and establish personalized treatment plans with the lowest risk of recurrence, toward improving patients’ overall quality of life, including their ability to breath and smell.
Join an expert panel of ENTs to explore the underlying pathways that lead to NPs and drive recurrent disease and treatment resistance. Panelists will also discuss the burdens faced by patients with NPs and evidence supporting the efficacy and safety of biologic agents for the treatment of refractory and recurrent NPs.
Do you have patients with NPs who could benefit from education on biologic treatment options? Direct your patients to MedLive.com to access the activity, “Making Your Voice Heard: Could Your Nasal Polyps Benefit from a Biologic Medicine?”
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Describe the inflammatory relationships between NPs and common T2-driven comorbidities
- Discuss safety, efficacy, and impacts on bothersome symptoms of current antibody targeted therapies for patients with moderate-to-severe CRSwNP
- Review patient-specific factors that help predict NP recurrence after standard treatment, including surgery
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
|
Stella Lee, MD Director of the Brigham Sinus Center Brigham and Women’s Hospital |
Consulting Fee (e.g., Advisory Board): AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron |
|
Noam Cohen, MD, PhD Professor of Otorhinolaryngology – Head and Neck Surgery Perelman School of Medicine at The University of Pennsylvania |
Consulting Fee (e.g., Advisory Board): Sanofi, Oyster Point Royalty: GeneOne Life Sciences |
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com
Technical Support:
For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.
082423_IML_CME_NasalPolyps_CMEInfo
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Asthma and Allergy Foundation of America (AAFA)
ACKNOWLEDGEMENT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
DATE OF RELEASE/EXPIRATION
This activity was released on August 24th, 2023 and is valid until October 24, 2024. Requests for credit must be made no later than October 24th, 2024
TARGET AUDIENCE
The intended audience for this program is ENTs, allergists, immunologists, specialty nurse practitioners and PAs, and other clinicians involved in the management of patients with nasal polyps (NPs).
STATEMENT OF NEED/PROGRAM OVERVIEW
In a recent outcomes survey of patients with nasal polyps (NPs), 88% responded that their treatment journey had been extremely burdensome and that lack of communication with their care team was a barrier to proper diagnoses or changes in therapeutic approaches. With increased awareness of newer, more effective treatments, frontline clinicians who manage NPs and chronic rhinosinusitis with nasal polyposis (CRSwNP) can help alleviate patients’ disease burden related to inadequate symptom control and recurrent disease.
Join an expert panel of allergy and ENT specialists to review the latest understanding of NPs and CRSwNP, including severe NPs and those at high risk for recurrence. Panelists will clarify the place of functional endoscopic sinus surgery (FESS) and biologic agents in the treatment of CRSwNP. After participating in the education, clinician participants will recognize biologics available to treat NPs and understand which patient characteristics justify their use. Participating allergists ENTs will also be prepared to collaborate in the care of patients with NPs and include them in effective, shared decisions about treatment.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Summarize the burden of disease and treatment for people with NPs, with a focus on outcomes that matter to patients, such as ability to smell, sleep, and be productive
- Describe the T2 inflammatory relationships between NPs and common comorbidities, such as asthma, aspirin-exacerbated respiratory disease (AERD), and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD)
- Explain how enhanced knowledge of NP endotypes and T2 inflammatory pathways can guide treatment decisions
- Review recent recommendations for the management of NPs with surgery and monoclonal antibodies, especially as they apply to the management of uncontrolled, severe NPs
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETE
This activity should take approximately 90 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
|
Stella Lee, MD Director of the Brigham Sinus Center Brigham and Women’s Hospital |
Consulting Fee (e.g., Advisory Board): AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Sanofi Regeneron |
|
Kathleen Buchheit, MD Assistant Professor of Medicine Brigham and Women’s Hospital |
Consulting Fee (e.g., Advisory Board): AstraZeneca, Regeneron, Sanofi, GSK Honoraria: GSK |
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities
CONTACT INFORMATION
Physician Accreditation Support:
For information about the physician accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at Support@ImmunologyLive.com.